NanoViricides' Clinical Stage, Broad-Spectrum, Antiviral Drug NV-387 Granted Orphan Drug Designation By US FDA Office Of Orphan Products Development

NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an "Orphan Drug Designation" (ODD) by the US FDA Office of Orphan Products Development (OOPD).

The orphan drug designation will qualify NanoViricides for incentives including:

Tax credits for qualified clinical trials;

Exemption from certain user fees;

Potential seven years of market exclusivity after approval;

according to the US FDA.